Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial

Por Gendelman, Howard E., Zhang, Yuning, Santamaria, Pamela, Olson, Katherine E., Schutt, Charles R., Bhatti, Danish, Shetty, Bhagya Laxmi Dyavar, Lu, Yaman, Estes, Katherine A., Standaert, David G., Heinrichs-Graham, Elizabeth, Larson, LuAnn, Meza, Jane L., Follett, Matthew, Forsberg, Erica, Siuzdak, Gary, Wilson, Tony W., Peterson, Carolyn, Mosley, R. Lee
Publicado no NPJ Parkinsons Dis (2017)